a model for the cellular and molecular chain of events leading to B cell proliferation in an antigen-induced immune response.
Materials and Methods
Mice. BALB/c, B10.A, B10.S(9R), and CBA/J mice were obtained from The Jackson Laboratory (Bar Harbor, ME). CBA/N mice were obtained from the Division of Research Services, National Institutes of Health. All mice were used at 8-12 wk of age.
Anti-lgM. Affinity column-purified goat antibody specific for mouse t* heavy chains (anti-t*) was prepared as previously described (20) .
Factor Preparations. EL4 supernatant was obtained by stimulating a cloned subline of EL4 thymoma with 10 ng/ml phorbol myristate acetate (PMA) as described elsewhere (21) . For some experiments, an IL-2-rich, BCGF-I-free component of these supernatants was obtained either by isoelectric focusing (IEF) or by phenyl Sepharose chromatography according to procedures published elsewhere (22, 23) . Purified human IL-2 kindly provided by Dr. Kendall A. Smith (Dartmouth Medical School, Hanover, NH) was prepared as follows. IL-2-containing supernatant was obtained from a phytohemagglutin (1.5 t*g/ml, Wellcome Reagents Limited, Beckenham, England) and PMA (50 ng/ml, Consolidated Midland Corp., Brewster, NY) stimulated human leukemic T cell line (Jurkat subclone 6.8). This supernatant was concentrated and applied to an immunoaffinity column constructed with an IgG~a monoclonal antibody to human IL-2. Bound IL-2 was eluted with 0.2 N acetic acid. The eluted material appeared to be a single polypeptide, 15,500 (Mr) when analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and showed a single spot on two-dimensional PAGE. For all preparations of IL-2, activity was measured via proliferation of the IL-2-dependent T cell clone HT2, as detailed elsewhere (13) .
Culture Medium. The culture medium used throughout was RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal calf serum (Reheis, Kankakee, 1L), penicillin (50 t*g/ml), streptomycin (50 t*g/ml), gentamicin (100 t*g/ml), L-glutamine (200 raM), and 2-mercaptoethanol (5 x 10 -s M).
Preparation of Antigen-reactive T Cell Lines. A continuously growing OVA-reactive T cell line was produced and maintained according to the procedure of Kimoto and Fathman (19) . Briefly, BALB/c mice were immunized in the footpad with 100 t*g OVA emulsified in complete Freund's adjuvant (Difco Laboratories Inc., Detroit, MI). Draining lymph nodes were removed 7 d later, T cells were purified by passage over nylon wool columns (24) , and then cultured in medium containing OVA I00 t*g/ml and -v-irradiated (3,300 R) syngeneic spleen cells as a source of antigen-presenting cells (APC). A long-term T cell line was established from this initial culture by serial restimulation of Ficoll-recovered T blasts (10"~/ml) with either "v-irradiated spleen cells (5 x 106/ml) alone, or -v-irradiated spleen cells plus antigen (100 t*g/ml). This line has been maintained in vitro without loss of antigen specificity for more than 18 too. The proliferative response of the line was periodically assayed by culturing 104 Ficoll-purified T cells together with 10 ~ irradiated (3,300 R) syngeneic spleen cells with or without OVA (100t*g/ml) in microtiter wells (Costar 3596) for 2.5 days, followed by a 16-h pulse with [3H]thymidine.
Several other antigen-reactive T cell lines were also developed as previously described (25) . Clones from these lines were derived by limiting dilution, plating the cells at an initial average density of 0.3 cells/well. The antigen specificities and genetic haplotypes of these lines were as follows: A3 is a B10.A-derived pigeon cytochrome c-specific T cell line; A2.9 is a B10.A pigeon cytochrome c-specific T cell clone; and 9R.1 is a B10.S(9R)-derived pigeon cytochrome c-specific T cell clone.
BCGF-I Assay. Full details of this co-stimulator assay are given elsewhere (13) . Briefly, splenic B cells were purified by the procedure of Leibson eta ]. (9) , then cultured at a density of 5 x 104 per 200 t*l medium in flat bottom 96-well microtiter plates. Some cultures contained affinity-purified goat anti-t* antibodies at 5-10 t*g/ml final concentration and/or dilutions of the various growth factor preparations. Cultures were incubated at 37 °C in a humidified atmosphere of air containing 7.5% CO2 for 3 d. The proliferative response of these cultures was determined by adding [~H] thymidine for the last 16 h of culture and measuring 3H-TdR incorporation. A relative unit of BCGF-I activity was defined as the amount of material required to produce 50% of the proliferation caused by a saturating amount of EL4 supernatant. Thus, the inverse of the dilution that produced 50% of the proliferation obtained with a saturating level of EL4 supernatant defined the number of relative units per milliliter (U/ml).
Biochemical Characterization of B Cell Growth Activity. The B cell co-stimulating activity in antigen-stimulated supernatants from the continuously growing OVA-reactive T cell was characterized biochemicaily by phenyl Sepharose chromatography and IEF. Full details of these procedures are given elsewhere (22, 23) .
Lyt Phenotype Analysis. The Lyt phenotype of BCGF-I producing T cells was assessed by selective cytotoxicity. Long-term OVA-reactive T cell blasts were recovered on Ficoll gradients following a 2-wk antigen-rest period, washed twice, then incubated at 2 × 105/ ml with either the rat anti-mouse Lyt-1 hybridoma (clone 53-7.3) and/or rat anti-mouse Lyt-2 hybridoma (clone 53-6.7) at final concentrations of 1:10. As these IgG2a monoclonal antibodies are not directly cytotoxic, it was essential to include the complement-binding monoclonal mouse anti-rat kappa antibody (MAR 18.5) to this cocktail in order to form a cytotoxic sandwich. The anti-Lyt and anti-kappa reagents were produced and generously provided by J. Ledbetter and L. Lanier, respectively (26, 27) . Following incubation for 30 rain at 4°C, the cells were washed, incubated for 45 min at 37°C with rabbit complement at 1:15 (Cedarlane, Low-tox), then washed twice in culture medium. To ensure comparison of equivalent precytotoxicity numbers of T cells, the entire contents of both control and test samples were then placed into a microtiter well in 200 t~l of culture medium containing 5 × 10 ~ ~,-irradiated syngeneic spleen cells and OVA (100 ~g/ ml). Supernatants were collected 24 h later and assayed for BCGF-I production.
Anti-IL-2 Receptor Antibody (a7D4).
A monoclonal rat anti-mouse IL-2 receptor antibody was produced by immunization of rats with the IL-2-dependent T cell line HT2. Full details of this antibody and its speciticity for the IL-2 receptor are presented elsewhere (28) . Briefly, this reagent reacts with a membrane antigen of 50,000-60,000 daltons expressed on activated but not resting lymphocytes (28) , immunoprecipitates cell associated IL-2 (28), and blocks proliferation of IL-2-dependent HT2 and CTLL cells (28) , but not the proliferation of LPS or anti-Ig activated B cells (T. Malek and M. Howard, unpublished observations).
Results

BCGF-I Activity in Antigen-stimulated T Cell Line
Supernatants. OVA-primed T cells were grown in continuous cell culture according to the procedure of Kimoto and Fathman (19) . Activation of this line to proliferate required specific antigen presented in the context of syngeneic irradiated spleen cells. Supernatants collected 4 d after stimulating the T cell line with OVA plus irradiated syngeneic spleen cells were tested for BCGF-I activity using the B cell co-stimulator assay developed previously (13) . Such supernatants (Tova sup) did not directly induce proliferation of purified B lymphocytes, but were capable of synergizing with anti-Ig antibodies to induce proliferation levels comparable to those achieved with induced EL4 supernatants ( 
amounts of EL4 sup, or vice versa (Fig. 2).
The above data strongly suggest that B cell co-stimulating activities in Tova sup and EL4 are identical. To confirm this, the active component of Tova sup was characterized by IEF and phenyl Sepharose chromatography and its properties compared to those previously reported (22, 23) for BCGF-I obtained from EL4 cells. The B cell co-stimulating factor in Tova sup had isoelectric points for 6.4 and 7.4 ( Fig. 3 ) and on phenyl Sepharose hydrophobic chromatography eluted in the 10-30% ethanediol fraction (Fig. 4) . Thus, by both procedures, it was indistinguishable from the BCGF-I in induced EL4 sup (22, 23) . From these biologicaI and biochemical data we therefore conclude that antigen-stimulated 
Characteristics of BCGF-I Production by Antigen-stimulated T Cell Lines. T o inves-
tigate the kinetics of BCGF-I production by antigen-activated T cell lines, OVAreactive T cells were collected after they had been cultured for 2 wk in the presence of APC but in the absence of antigen. Such "rested" cells were stimulated with OVA plus irradiated syngeneic spleen cells, and cell-free supernatants were collected 1, 2, 3, 4, and 5 d thereafter. Excellent BCGF-I activity was detected in each supernatant, with essentially no quantitative difference betweeen the different time points (Fig. 5) . The amount of BCGF-I produced within 24 h of stimulating 105 OVA-reactive T cells was comparable to that produced by 20 times as many EL4 cells stimulated for 48 h with phorbol myristate acetate (Fig.  5) . No BCGF-I was detected in supernatants collected from cultures of irradiated syngeneic spleen plus OVA (Fig. 5) . Small but detectable amounts of BCGF-I were found in supernatants from antigen-free cultures containing T cell plus irradiated syngeneic spleen cells (Fig. 5 ). As some proliferation was also seen under these latter conditions, this production might reflect either a small degree of antigen carry-over or a small degree of autologous MLR activity by cells in this line. No BCGF-I activity was found in supernatants collected from OVAreactive T cells stimulated with antigen presented in the context of irradiated allogeneic spleen cells (data not shown), demonstrating that induction of BCGF-I production is H-2 restricted. Treatment of the OVA-reactive T cells with cytotoxic anti-Lyt reagents before antigenic stimulation revealed that the cells in this line which are involved in BCGF-I production bear the Lyt 1 +2-phenotype (Fig. 6 ). As few Lyt 2 + T cells are propagated by this method of continuous antigen-induced T cell cultivation, it should not, however be concluded that Lyt 2 + T cells fail to produce BCGF-I. Finally, the relationship betwen T cell density and BCGF-I production (Fig. 7 ) was found to be nonlinear and showed that as few as 104 OVA-reactive T cells produced detectable levels of BCGF-I within 24 h of stimulation with antigen plus irradiated syngeneic spleen cells.
IL-2 Induces BCGF-I Production by T Cell
Lines. Current models of T cell activation propose that antigen presented in the context of syngeneic APC induces resting T cells to express IL-2 receptors, and that IL-2 causes these activated lymphocytes to proliferate (29) . The above experiments demonstrate that in the case of Lyt 1 + T cells at least, this activation process is accompanied by induction of BCGF-I release. To test whether the stimulus for lymphokine release is also provided by IL-2, OVA-specific T cells were collected at the end of a 2-wk antigen rest period and stimulated with purified BCGF-I-free preparations of IL2. Cell-free supernatants collected 2 d later were assayed for BCGF-I activity. Both phenyl Sepharose-purified IL-2 from PMA-induced EL4 supernatant and affinity-purified human IL-2 induced 105 OVA-specific T cells to produce substantial amounts of BCGF-I (Table I) . Similar results were obtained using IEF purified IL-2 from PMA-induced EL4 supernatant (data not shown).
In all experiments of this type, the level of IL-2-induced BCGF-I production corresponded to between 10 and 20% of that achieved when T cells were stimulated with antigen in the context of syngeneic spleen cells (Table I) . Titration of the amount of IL-2 required for BCGF-I production showed that as little as 10 U/ml IL-2 induced 105 T cells to produce optimum amounts of BCGF-I (Fig. 8 ). This production was totally blocked by a monoclonal rat antimouse IL-2 receptor antibody (designated a7D4) but not by a monoclonal rat anti-mouse Lyt-1 antibody (Fig. 8) . As the anti-IL-2 receptor antibody by itself showed no intrinsic blocking effects in the BCGF-I assay (M. Howard and T. Malek, unpublished data), these data indicate that BCGF-I production in the above experiments had indeed resulted from a direct effect of IL-2 at the T cell's IL-2 receptor. While abrogation of IL-2-induced BCGF-I production in the above antibody-blocking experiments was accompanied by elimination of the T cell proliferative response (Table II) , separate experiments showed that nonproliferating irradiated T cells were capable of producing optimum amounts of * 105 antigen-rested T cells were cultured with various stimuli for 2 d; supernatants were harvested and assayed for BCGF-I. Parallel cultures lacking T cells were included to control for any BCGF-I derived from the stimulant. ~; Mouse IL-2 = phenyl Sepharose-purified IL-2 from PMA-induced EL4 supernatant added to cultures at ~ 10 U/ml. 0 Human IL-2 --affinity-purified IL-2 from induced Jurkat supernatant, provided by Dr. K. Smith, added to cultures at ~25 U/ml. ! Syngeneic spleen cells were cultured with OVA 100 #g/ml for 3 h, washed, irradiated at 3,300 fads, and added to cultures at 5 x 106/ml. Control experiments showed that 56 U/ml of the partially purified IL-2 contained <2 U/ml BCGF-I activity. All groups represent duplicate cultures.
BCGF-I in response to either IL-2 or antigen-pulsed APC (Table III) . Thus, while proliferation and lymphokine release are apparently mediated via the same receptor-ligand interactions, they are nevertheless independent events. The results of Table III also demonstrate that Con A, particularly when presented in the context of syngeneic irradiated spleen, is capable of inducing antigen-reactive T cells to secrete BCGF-I. While this observation is readily explained by Con Ainducing T cells to secrete IL-2 which in turn induces BCGF-I production, it is nevertheless intriguing in light of the apparent difficulty of detecting BCGF-I in Con A-induced spleen cell supernatants (M. Howard, unpublished observations). * 10 ~ antigen-rested T cells were cultured with the various stimuli listed. Induction of BCGF-I production was assessed by assaying the amount of BCGF-I in supernatants collected 2 d later. Induction of proliferation was assessed via the uptake of ~H-TdR on day 3. For details of the mouse IL-2 and OVA pulsed irradiated spleen cell stimulants, refer to Table I . For details of the a7D4 and aLytl antibodies, refer legend to Fig. 8 . Table I .
TABLE III
BCGF-I Production by and Proliferation of Nonirradiated and Irradiated T Cells following Stimulation
Con A was used at 1 #g/ml.
Interestingly, the anti-IL-2 receptor antibody used in the above experiments failed to abrogate either BCGF-I production or proliferation ofT cells stimulated with antigen and syngeneic APC (Table II) . Possible explanations for this observation are discussed below. Finally, to test the generality of the above findings, the same BCGF-I induction experiments were performed using other antigen-reactive T cell lines. Three long-term lines, two of which had additionally been cloned by limit dilution, were used for this purpose. Two of these three lines produced BCGF-I in response to specific antigen presented in the context of syngeneic spleen cells (Table IV) ; all three of the lines produced BCGF-I in response to phenyl Sepharose-purified IL-2 (Table IV) . In contrast to the above situation with the OVA-reactive T cell line, IL-2 proved equal to or better than presented antigen in inducing BCGF-I * Conditions for BCGF-I production as in Table 1 . * For details on antigen specificity and genetic haplotype of T cell lines, see Materials and Methods. ! IL-2 --phenyl Sepharose-purified mouse IL-2, added at ~10 U/ml. This mixture contained <2 U/ml BCGF-I.
production by these T cell lines (Table IV) . As cloning of T cell lines involves an initial IL-2-dependent propagation step, this may simply reflect selection during cloning of T cells that are highly IL-2-responsive. From these data we conclude that BCGF-! production is a common feature of long-term antigen-reactive T cell lines when stimulated either with presented antigen or IL-2.
Discussion
This study demonstrates the production of murine BCGF-I by antigen-reactive long-term T cell lines and T cell clones following stimulation with either antigen presented in the context of syngeneic spleen cells, or alternatively IL-2. While BCGF-I has been found in supernatants of T cell hybridomas, lymphomas, and alloreactive T cell clones (13, (30) (31) (32) , this is the first demonstration of its production by normal mouse T cells in response to antigenic stimulus. As most other sources of BCGF-I require induction by PMA or Con A, the current source provides the added advantage of being mitogen-free. The fact that BCGF-I production by the OVA-reactive T cell line used throughout most of this study was substantially greater using presented antigen as the inductant rather than IL-2 can be readily explained by a consideration of the physiology of this type of T cell line. The optimum procedure for growing such lines on alternate cycles of antigen-rest and antigen-exposure is consistent with the fact that T cells lose their IL-2 receptors some time after activation (29) . Thus, at the end of a 2-wk antigen-rest period the T cell lines will most likely comprise a mixture of IL-2-receptor-bearing cells and cells that have already lost their IL-2 receptors. Whereas IL-2 induction will only encompass the first of these populations, antigen plus APC has the potential to recruit both i.e., to re-activate expression of IL-2-receptors and to generate IL-2 to act on such receptors. In contrast, the antigen-reactive T cell clones analysed for BCGF-I production showed the reverse preference for IL-2 rather than presented antigen as optimum inductant. As mentioned above, this may reflect selection for enhanced IL-2 responsiveness during the cloning procedure.
Our observation that antibodies to the IL-2 receptor block BCGF-I production in response to IL-2 but not in response to presented antigen, raises the possibiity that a mechanism independent of engagement of the IL-2 receptor can be used to cause BCGF-I production. Since [3H]thymidine uptake by these cells in response to antigen and APC is also not blocked by the anti-receptor antibody, this would further imply that an IL-2-independent mechanism may exist for proliferation of these T cells. Such a conclusion, however appears to us to be premature. The results might equally well be explained by the induction on T cells of large numbers of IL-2 receptors as a result of stimulation by antigen and APC, making such cells much more difficult to block than cells simply treated with IL-2. Alternatively, antigenic stimulation might induce the T cells to produce IL-2 and IL-2 receptors simultaneously. Under these circumstances receptor-ligand complexes could be formed intracytoplasmically, i.e. before their surface expression, thereby removing all opportunity for an extracellular antibody to compete in the interaction. Thus, antigen-induced proliferation and BCGF-I production by T cells may also be mediated by the IL-2 receptor, despite the fact that both processes are refractory to the blocking effects of the anti-IL-2 receptor antibody. This paper contributes to our growing knowledge of the lymphokine cascade that apparently regulates the effector mechanisms of the immune response. Others have shown that T cell-derived colony-stimulating-factor induces macrophages to release IL-1, which in turn stimulates T cells to release IL-2 (reviewed in reference 22 ). Here we demonstrate that IL-2 in turn acts on T cells to release the B cell proliferation cofactor BCGF-I. Thus, IL-2 is a bifunctional mediator capable of inducing T cells to proliferate and/or secrete BCGF-I. Such plurifunction has previously been reported in the case of the biochemically similar lymphokine colony stimulating factor, a mediator that acts on macrophages, inducing both proliferation (33) and effector cell function (34, 35) . Whether all B cell-specific cofactors are induced by IL-2 is not yet clear. Antigen stimulation of long-term T cell lines similar to those used in this study is known to cause release of other B ceil-specific cofactors (36) (37) (38) , but the mechanisms governing those events have not yet been elucidated. Preliminary evidence from Swain and colleagues suggests that IL-2 induces an allorective T cell line to produce B cell differentiation factors and the second B cell growth factor BCGF-II (reference 39; S. Swain, personal communication). In contrast however, Asano et al. (40) have demonstrated that antigen-reactive T cell clones are capable of providing helper T cell function in an antibody response at antigen concentrations below which proliferation and thus, presumably IL-2 release are observed. Whether or not IL-2 induces all B cell-specific cofactors, one should not regard it as a universal lymphokine inductant. At least in the case of interferon, lymphokine production by antigen-reactive T cell clones has been segregated from proliferation and IL-2 induction (41). The fact that IL-2 causes production of at least some B cell-specific interleukins may well explain the current controversy regarding the role of IL-2 in B cell immunity (reviewed in reference 18). The current studies demonstrate that as few as 104 T cells produce detectable amounts of BCGF-I. While proponents of IL-2 acting directly on B cells may feel confident that their starting B cell population is free of this level of T cell contamination, an even lower level may well expand to such a number in the presence of IL-2 during the 3-5-d culture periods generally used.
The demonstration of BCGF-I production by antigen-reactive MHC-restricted helper T cells prompts some modification of current models that divide B cell triggering into either factor-mediated or involving cognate T cell interactions (discussed in reference 18). In light of the present study, cognate T cell interactions will presumably generate at least some B cell-specific interleukins. Thus it seems more likely that both pathways will use similar, if not the same, cofactors. The apparent difference between those B cells that appear to utilize direct interactions with T cells for their activation and those B cells that do not could be explained at the level of cofactor receptor expression, i.e., that the role of cognate T cell interaction may be to induce a membrane receptor for a B cellspecific interleukin; other B cells may already express this receptor or develop it in response to membrane immunoglobulin cross-linkage by antigen, thus bypassing the need for a cognate T cell signal. Testing of this model and direct demonstration that the cognate interaction pathway utilizes factors will hopefully be possible when antibodies against the factors or their membrane-bound receptors are developed.
Summary
Antigen-activated T iymphocytes produce within 24 h of stimulation a factor that is indistinguishable biochemically and functionally from the B cell costimulating growth factor, BCGF-I, originally identified in induced EL4 supernatants: Supernatants from antigen-stimulated T cell lines are not directly mitogenic for resting B cells, but synergize in an H-2-unrestricted manner with anti-Ig activated B cells to produce polyclonal proliferation but not antibodyforming-cell development; biochemical studies reveal the B cell co-stimulating factor present in antigen-stimulated T cell line supernatants is identical by phenyl Sepharose chromatography and isoelectric focusing (IEF) to EL4 supernatant BCGF-I. We thus conclude that normal T cells produce BCGF-I in response to antigenic stimulation.
Analysis of the mechanism of BCGF-I production by antigen-stimulated T cells showed that optimum amounts of BCGF-I were obtained as quickly as 24 h poststimulation, and that the factor producing cells in the T cell line investigated bore the Lyt-l+2 -phenotype. As few as 104 T cells produced sufficient BCGF-I to support the proliferation of 5 × 104 purified anti-Ig activated B cells. Finally, the activation of normal T cell lines to produce BCGF-I required either antigen presented in the context of syngeneic antigen-presenting cells (APC) or interleukin 2 (IL-2).
Note added in proof'. After this paper was submitted, a working group on B cell factors met in Kyoto and proposed that BCGF-I be designated BSF (B cell stimulatory factor).
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